Document is current
Any future updates will be listed below
-
Authors
Schulz, Felicitas
Roggenbuck, Claudia
Kündgen, Andrea
Kasprzak, Annika
Nachtkamp, Kathrin
Jäger, Paul
Dietrich, Sascha
Kobbe, Guido
Germing, Ulrich
Neumann, Frank
-
Funding
Funding for this research was provided by:
Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
- License Information
-
More Information
Article History
Received: 24 September 2024
Accepted: 6 January 2025
First Online: 11 January 2025
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Heinrich-Heine University in Duesseldorf.
: Informed consent was obtained from all subjects in the study.
: F.N.: Stock in Gilead and 270Bio, equity in ORNA, MPM entrepreneur partner. G.K.: Advisory Role, Speaker Honoraria and/or travel support: MSD, Pfizer, Amgen, Novartis, Gilead, BMS-Celgene, Abbvie, Medac, Biotest, Takeda, Eurocept. Financing of scientific research: BMS-Celgene, Amgen, Abbvie, Eurocept, Medac. U.G.: Institutional research support: BMS, Abbvie, Jazz. Speaker honoraria: BMS, Jansen.
